Literature DB >> 7902382

A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus.

S A Bozzette1, J A McCutchan, S A Spector, B Wright, D D Richman.   

Abstract

The association between isolation of the syncytium-inducing (SI) phenotype of human immunodeficiency virus (HIV) and unfavorable clinical and immune status was evaluated in a cross-sectional study. Data on HIV phenotype were available for 341 of 878 persons entering clinical trials of antiretroviral therapies. Patients with SI virus were demographically similar to those with non-SI (NSI) virus but were more likely to have a diagnosis of AIDS and detectable circulating HIV p24 antigen. Patients with SI virus also had a lower CD4+ cell count and a higher serum level of beta 2-microglobulin. The association between phenotype and present status was explained statistically by CD4+ cell count. Phenotype, serum level of beta 2-microglobulin, and the presence of detectable p24 antigen were all independent predictors of present CD4+ cell count. The likelihood of finding SI virus increased with unfavorable virologic and immunologic parameters and varied with the amount of prior antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902382     DOI: 10.1093/infdis/168.6.1374

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Alejandra Ramos; Donald E Mosier
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.

Authors:  Yana Kiselyeva; Rebecca Nedellec; Alejandra Ramos; Cristina Pastore; Leonid B Margolis; Donald E Mosier
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

4.  Host cell antigenic profile acquired by HIV-1 is a marker of its cellular origin.

Authors:  I Abbate; M R Capobianchi; S Fais; C Castilletti; F Mercuri; P Cordiali Fei; F Ameglio; F Dianzani
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Acquisition of syncytium-inducing HIV-1 strains during therapy with zidovudine alone or combined with alpha interferon or didanosine.

Authors:  Y Torres; M Leal; C Rey; F J Medrano; A Sánchez-Quijano; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

6.  Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection.

Authors:  Gabriel A Wagner; Mary E Pacold; Edgar Vigil; Gemma Caballero; Sheldon R Morris; Sergei L Kosakovsky Pond; Susan J Little; Douglas D Richman; Sara Gianella; Davey M Smith
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

7.  APOBEC3G/F as one possible driving force for co-receptor switch of the human immunodeficiency virus-1.

Authors:  Eva Heger; Alexander Thielen; Ramona Gilles; Martin Obermeier; Thomas Lengauer; Rolf Kaiser; Susanna Trapp
Journal:  Med Microbiol Immunol       Date:  2011-05-15       Impact factor: 3.402

Review 8.  Virus and target cell evolution in human immunodeficiency virus type 1 infection.

Authors:  D E Mosier
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

9.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

10.  Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Authors:  Jing Lu; Prakash Sista; Françoise Giguel; Michael Greenberg; Daniel R Kuritzkes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.